THERAFLU WARMING RELIEF FLU AND SORE THROAT OTC
Generic Name and Formulations:
Acetaminophen 325mg, diphenhydramine HCl 12.5mg, phenylephrine HCl 5mg; per 15mL; liq; contains potassium 5mg/15mL, sodium 7mg/15mL; cherry flavor.
Novartis Consumer Health
Indications for THERAFLU WARMING RELIEF FLU AND SORE THROAT :
Minor aches and pains. Headache. Fever. Sneezing. Rhinorrhea. Nasal and sinus congestion. Itchy eyes, nose, throat. Sore throat.
30mL every 4 hours. Max 180mL/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen, diphenhydramine (including skin) products.
Liver disease. Heart disease. Hypertension. Thyroid disease. Diabetes. Glaucoma. COPD. Asthma. GI or GU obstuction. Pregnancy. Nursing mothers.
Analgesic + antihistamine + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effect of sympathomimetics. Antagonizes antihypertensives. Increased CNS effects with other CNS depressants.
Drowsiness, nervousness, dizziness, insomnia, anticholinergic effects, excitability in children; hepatotoxicity (overdosage).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline